Concert Pharmaceuticals

September 03, 2019

Concert squares up to Pfizer in alopecia Jak bout

Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.

Aclaris’s alopecia Jak might not be worth its Salt

June 17, 2019

Incyte hopes its cream can rise to the top

April 09, 2019

Concert out of tune after patent stumble

February 26, 2019

Xeljanz warning Jaks up safety concerns

An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.

November 12, 2018

Concert’s value shaved after early alopecia win

September 21, 2018

Upcoming events – Phase II readouts loom for Concert and Reata

Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.

October 25, 2017

Abbvie’s Jak flashes a warning for the whole class

March 29, 2017

Vertex investors toast birth of the son of Orkambi

March 06, 2017

Vertex’s cystic fibrosis strategy in tune with Concert buy

December 15, 2016

Eucrisa thumbs up validates Pfizer’s takeover strategy – partly

Load More